MMS Q2 Deep Dive: Federal Segment Strength and Policy Tailwinds Support Guidance Upgrades

Government services provider Maximus (NYSE:MMS) announced better-than-expected revenue in Q2 CY2025, with sales up 2.5% year on year to $1.35 billion. The company expects the full year’s revenue to be around $5.43 billion, close to analysts’ estimates. Its non-GAAP profit of $2.16 per share was 40.7% above analysts’ consensus estimates.

Is now the time to buy MMS? Find out in our full research report (it’s free).

StockStory’s Take

Maximus delivered second quarter results that significantly exceeded Wall Street’s expectations, leading to a strong market reaction. Management attributed the outperformance to elevated volumes in its U.S. Federal Services segment, particularly in clinical programs, and operational leverage from earlier technology investments. CEO Bruce Caswell highlighted, “We realized 15% growth in adjusted EBITDA, and our U.S. Federal Services segment was the main driver of our consolidated results.” The team also cited resilient execution on performance-based contracts and successful adaptation to evolving government priorities.

Looking ahead, Maximus' updated guidance for the year reflects management’s confidence in continued demand for its government services, especially as new policy changes take effect. The company expects that evolving Medicaid and SNAP regulations, as well as new federal contracts, will support growth. CFO David Mutryn noted, “We are raising guidance again this year to not only account for the performance this quarter, but to also capture improved clarity for the upcoming fourth quarter.” Management is also preparing for opportunities stemming from legislative changes and a growing pipeline in defense and adjacent federal markets.

Key Insights from Management’s Remarks

Management credited the quarter’s strong performance to increased federal program volumes, operational efficiency improvements, and early benefits from recent legislative and regulatory changes.

• Federal clinical program expansion: Maximus reported that higher volumes in federal clinical contracts, particularly those requiring medical expertise, drove organic growth and improved segment margins. Management pointed to deliberate investments in clinical capacity that enabled the company to scale efficiently in response to demand fluctuations.
• Operational leverage from technology: The company highlighted gains from ongoing investments in workflow optimization and digital infrastructure. These initiatives allowed Maximus to process greater work output with improved cost efficiency, supporting stronger adjusted EBITDA margins.
• Legislative impacts in Medicaid and SNAP: Management discussed the One Big Beautiful Bill Act and its implications, including new eligibility and work requirements for Medicaid and stricter accuracy rules for SNAP. Maximus has begun assisting state clients to comply with these requirements, anticipating further growth as states implement changes.
• Defense sector contract win: The company secured a $77 million U.S. Air Force contract for cybersecurity and cloud services, reflecting successful expansion into defense and adjacent federal markets. Management believes that recent certifications, such as CMMC Level 2, are opening new addressable opportunities.
• Book-to-bill and pipeline context: While the trailing 12-month book-to-bill ratio was below 1.0, management emphasized the importance of on-contract growth and a $44.7 billion pipeline, with a majority tied to the U.S. Federal Services segment. They stressed that pipeline timing and backlog dynamics are key for interpreting future growth.

Drivers of Future Performance

Maximus expects that legislative-driven changes, ongoing efficiency initiatives, and a growing federal pipeline will shape its financial outlook for the next year.

• Medicaid and SNAP policy shifts: Management anticipates that new federal mandates for Medicaid eligibility redeterminations and work requirements, along with SNAP payment error reforms, will create incremental business for Maximus starting late next year. However, the company forecasts that most revenue impact will materialize in 2027, with some states potentially acting earlier.
• Federal contract pipeline and defense expansion: The company highlighted a robust pipeline across civilian, health, and defense agencies, with recent wins in defense offering longer-term growth potential. Management expects its CMMC Level 2 certification and strategic hires to drive further wins in national security and technology modernization projects.
• Budget and volume uncertainties: Management noted that state and federal budget pressures could introduce near-term headwinds. At the same time, efficiency objectives at the agency level may generate opportunities for new technology-led service models. The company is monitoring the mix of recurring and nonrecurring volumes to assess margin sustainability.

Catalysts in Upcoming Quarters

Moving forward, the StockStory team will be watching (1) the pace of state adoption and implementation of Medicaid and SNAP policy changes, (2) the conversion of pipeline opportunities into new federal and defense contracts, and (3) the normalization of working capital and free cash flow as payment cycles stabilize. The impact of ongoing technology investments and the outcome of efficiency initiatives in federal and state agencies will also be important indicators.

Maximus currently trades at $82.65, up from $74.79 just before the earnings. Is the company at an inflection point that warrants a buy or sell? The answer lies in our full research report (it’s free).

Our Favorite Stocks Right Now

Donald Trump’s April 2025 "Liberation Day" tariffs sent markets into a tailspin, but stocks have since rebounded strongly, proving that knee-jerk reactions often create the best buying opportunities.

The smart money is already positioning for the next leg up. Don’t miss out on the recovery - check out our Top 5 Strong Momentum Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025).

Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+782% five-year return). Find your next big winner with StockStory today.

StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.